The NRF-2/HO-1 Signaling Pathway: A Promising Therapeutic Target for Metabolic Dysfunction-Associated Steatotic Liver Disease
Na Li,Liyuan Hao,Shenghao Li,Jiali Deng,Fei Yu,Junli Zhang,Aiyu Nie,Xiaoyu Hu
DOI: https://doi.org/10.2147/jir.s490418
IF: 4.5
2024-11-04
Journal of Inflammation Research
Abstract:Na Li, 1, 2 Liyuan Hao, 1, 2 Shenghao Li, 1, 2 Jiali Deng, 1, 2 Fei Yu, 1, 2 Junli Zhang, 3 Aiyu Nie, 1, 2 Xiaoyu Hu 2 1 Department of Clinical Medicine, Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China; 2 Department of Infectious Diseases, Hospital of Chengdu University of Traditional Chinese Medicine, Chengdu, People's Republic of China; 3 Jiangsu Provincial Hospital of Traditional Chinese Medicine, Nanjing, People's Republic of China Correspondence: Xiaoyu Hu, Hospital of Chengdu University of Traditional Chinese Medicine, No. 39 Shi-Er-Qiao Road, Chengdu, Sichuan Province, 610075, People's Republic of China, Email Metabolic dysfunction-associated steatotic liver disease (MASLD) is a progressive liver disorder with a rising prevalence. It begins with lipid accumulation in hepatocytes and gradually progresses to Metabolic-associated steatohepatitis (MASH), fibrosis, cirrhosis, and potentially hepatocellular carcinoma (HCC). The pathophysiology of MASLD is complex and involves multiple factors, with oxidative stress playing a crucial role. Oxidative stress drives the progression of MASLD by causing cellular damage, inflammatory responses, and fibrosis, making it a key pathogenic mechanism. The Nuclear Factor Erythroid 2-Related Factor 2 / Heme Oxygenase-1 (Nrf2/HO-1) signaling axis provides robust multi-organ protection against a spectrum of endogenous and exogenous insults, particularly oxidative stress. It plays a pivotal role in mediating antioxidant, anti-inflammatory, and anti-apoptotic responses. Many studies indicate that activating the Nrf2/HO-1 signaling pathway can significantly mitigate the progression of MASLD. This article examines the role of the Nrf2/HO-1 signaling pathway in MASLD and highlights natural compounds that protect against MASLD by targeting Nrf2/HO-1 activation. The findings indicate that the Nrf2/HO-1 signaling pathway holds great promise as a therapeutic target for MASLD. Keywords: the NRF-2/HO-1 signaling pathway, antioxidants, anti-inflammatory, natural compounds, non-alcoholic fatty liver disease Graphical Non-alcoholic fatty liver disease (NAFLD) is a condition characterized by excessive fat accumulation in the liver, excluding alcohol and other specific causes of liver damage. 1 To more accurately reflect the metabolic basis of the disease, an international expert panel introduced a new term in 2020: Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD), which replaced the old term "Non-Alcoholic Fatty Liver Disease" (NAFLD). 2 In 2023, a multi-society Delphi consensus statement on the new nomenclature for fatty liver disease introduced the term Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and formally discontinued the use of NAFLD. 3 Based on disease progression, MASLD can be classified into four distinct stages: simple steatosis, Metabolic-Associated Steatohepatitis (MASH), fibrosis, and cirrhosis. 4 The clinical manifestations of MASLD are diverse, with the majority of patients being asymptomatic. However, some patients may report symptoms such as fatigue, discomfort in the right upper quadrant, hepatomegaly, acanthosis nigricans, and lipomas. 5 In more severe cases, symptoms like jaundice, loss of appetite, nausea, and vomiting may occur. 6 Furthermore, MASLD is closely associated with metabolic and systemic diseases such as cardiovascular disease, obesity, type 2 diabetes, and sarcopenia. These conditions are not only common complications of MASLD, 7–9 but may also exacerbate its progression, leading to further deterioration of the patient's condition. 10–12 MASLD has become the most common liver disease worldwide and is expected to be the leading cause of end-stage liver disease in the coming decades. 13,14 According to statistics, the global prevalence of MASLD ranges from 25% to 34%, with 30% in Europe, 35% in South and North America, and 29.29% in Asia. Notably, the prevalence in Southeast Asia is as high as 42%. 15–18 The mortality rate for individuals with MASLD is 1.6 times higher than that of the general population, 19–21 with an all-cause mortality rate of 12.60 per 1000 person-years, posing a significant public health crisis. 22 Among the management strategies for MASLD, weight loss is considered one of the most effective measures; however, patients often struggle to maintain long-term adherence in practice. 23,24 Pharmacological and surgical treatments have also been shown to improve patients' metabolic conditions and increase survival rates effectively. Commonly used m -Abstract Truncated-
immunology